Scholars@Duke
Chenyu Lin

Chenyu Lin

Assistant Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
2400 Pratt Street, Suite 5000, Durham, NC 27705
ORCID iDhttps://orcid.org/0000-0002-4542-4232
2400 Pratt Street, Suite 5000, Durham, NC 27705

Scholarly Works - Conferences

Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Conference Blood · November 3, 2025 AbstractIntroduction: Isocitrate dehydrogenase (IDH) mutations are observed in ~20% of patients with acute myeloid leukemia (AML). In the U ... Full text Cite

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Conference Blood · November 3, 2025 AbstractIntroduction:Owing to inherent chemoresistance and poor outcomes in TP53 mutant (m) acute myeloid leukemia (AML), treatment strateg ... Full text Cite

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Conference Blood · November 3, 2025 AbstractBackground: Hypomethylating agent (HMA) with venetoclax (VEN) is used in clinical practice for frontline management of patients wit ... Full text Cite

Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease

Conference Blood · November 3, 2025 AbstractBackground and Significance: Current therapies for steroid-refractory chronic graft versus host disease (SR-cGVHD) feature limited ... Full text Cite

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel

Conference Blood · November 3, 2025 AbstractIntroduction: CD19-directed CAR T-cell (CAR-T) therapy has substantially improved clinical outcomes for adults with relapsed or ref ... Full text Cite

Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world

Conference Blood · November 3, 2025 AbstractIntroduction: Brexucabtagene autoleucel (Brexu-cel) is a CD19-targeted chimeric antigen receptor (CAR-)T cell therapy approved for ... Full text Cite

Remote multi-vital sign monitoring allows earlier detection of cytokine release syndrome after bispecific T cell engager and chimeric antigen receptor T cell therapies

Conference Blood · November 3, 2025 AbstractIntroduction: Cytokine release syndrome (CRS) is a systemic inflammatory condition seen in 50-80% of patients after bispecific T ce ... Full text Cite

Real-world survival outcomes with first-line venetoclax therapy in AML

Conference Blood · November 3, 2025 AbstractIntroduction: Venetoclax, a selective BCL-2 inhibitor combined with a hypomethylating agent (azacitidine or decitabine), has become ... Full text Cite

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Conference Blood · November 3, 2025 AbstractBackground and significance: T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) accounts for 15% of pediatric and 25% of a ... Full text Cite

Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma

Conference Blood · November 3, 2025 AbstractBackground: Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has revolutionized treatment ... Full text Cite

Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia

Conference Blood · November 5, 2024 Introduction: TP53 mutations are found in 18% of adult patients (pts) with acute lymphoblastic leukemias (ALL), and portends poor prognosis (Saygin, Blood Cancer Discov 2024). TP53 mutati ... Full text Cite

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Conference Blood · November 5, 2024 Introduction:Brexucabtagene Autoleucel (brexu-cel) is the first CD19-targeting chimeric antigen receptor (CD19.CAR) T-cell therapy approved for the tre ... Full text Cite

Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction

Conference Blood · November 5, 2024 Introduction:Mutations in FMS-like tyrosine kinase 3 (FLT3) are one of the most common genetic alterations in acute myeloid leukemia (AML), with intern ... Full text Cite

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Conference Blood · November 5, 2024 Introduction: Chimeric Antigen Receptor (CAR)- T cell therapy has revolutionized the treatment of hematologic malignancies. However, access to CAR-T therapy remains limited, especially fo ... Full text Cite

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Conference Blood · November 5, 2024 Introduction: Brexucabtagene autoleucel (brexu cel) is a CD19-targeted chimeric antigen receptor (CAR) T cell therapy approved for the treatment of adults with relapsed/refractory (R/R) a ... Full text Cite

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Conference Blood · November 5, 2024 Background: Teclistamab (Tec) received regulatory approval for the treatment of relapsed refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. The risk of CRS and ICANS with T ... Full text Cite

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Conference Blood · November 5, 2024 Background: Teclistamab (Tec), a first-in-class BCMA bispecific T-cell antibody, received regulatory approval for the treatment of RRMM based on the MajesTEC-1 study [Moreau et al, NEJM, ... Full text Cite

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Conference Blood · November 5, 2024 Background: Tec is a BCMA-directed bispecific antibody (BsAb) approved for RRMM after ≥4 prior lines of therapy (LOT) based on the MajesTEC-1 trial. However, patients who had previously r ... Full text Cite

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Conference Blood · November 2, 2023 Cellular Immunotherapies: Late Phase and Commercially Available TherapiesThe Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults w ... Full text Cite

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Conference Blood · November 2, 2023 Introduction:Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for adults with relapsed/refractory B-cell acute lym ... Full text Cite

Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Conference Blood · November 2, 2023 IntroductionIn October 2021, brexucabtagene autoleucel (brexu-cel) received U.S. FDA approval as the first CAR T-cell therapy for adults with relapsed/refractory (r/r) B-cell acute lymph ... Full text Cite

Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)

Conference Blood · November 2, 2023 Introduction: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B- ... Full text Cite

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Conference Blood · November 2, 2023 BackgroundBrexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR-T) cell therapy that recently received U.S. FDA approval as the first CAR-T cell ... Full text Cite

Impact of Social Determinants of Health and Novel Therapies on the Outcomes of Relapsed and Refractory Diffuse Large B Cell Lymphoma

Conference Blood · November 2, 2023 Introduction:Outcomes for patients with relapsed and refractory diffuse large B cell lymphoma (R/R DLBCL) have improved dramatically with the recent approvals of chimeric antigen recepto ... Full text Cite

Tolerability and Outcomes of Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction

Conference Blood · November 2, 2023 Introduction:There is limited data on the outcomes and tolerability of Bruton Tyrosine Kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL) in patients with severe renal dysfun ... Full text Cite

Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis

Conference Blood · November 2, 2023 Background: Chimeric Antigen Receptor T-Cell therapies (CAR-T) are effective in a variety of hematologic (hem) malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell-ass ... Full text Cite

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

Conference Blood · November 2, 2023 Introduction:In October 2021, the FDA approved brexu-cel for the treatment of adults ≥ 18 years old with R/R B-ALL. Following this approval, a consortium of cancer centers was formed acr ... Full text Cite

Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service.

Conference Journal of Clinical Oncology · June 1, 2023 1602 Background: Telemedicine is increasingly used in cancer care but has mostly been applied to surveillance and oral therapy rather than parenteral treatments. In the U.S. Veterans Affairs National TeleOncology service (NTO), p ... Full text Cite

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

Conference Transplant Cell Ther · May 2023 Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has demonstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although the early ... Full text Link to item Cite

Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study

Conference Stem Cells Translational Medicine · September 6, 2022 AbstractIntroductionOmidubicel, an advanced cell therapy used for allogeneic hematopoietic stem cell transplant has demonstrated faste ... Full text Cite